Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes in Treatment-Naïve Patients With Metastatic Extremity Osteosarcoma Treated With OGS-12, a Novel Non-High-Dose Methotrexate-Based, Dose-Dense Combination Chemotherapy, in a Tertiary Care Cancer Center.
Bajpai J, Chandrasekharan A, Simha V, Talreja V, Karpe A, Pandey N, Singh A, Rekhi B, Vora T, Ghosh J, Banavali S, Gupta S. Bajpai J, et al. Among authors: talreja v. J Glob Oncol. 2018 Sep;4:1-10. doi: 10.1200/JGO.17.00137. J Glob Oncol. 2018. PMID: 30241240 Free PMC article.
Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
Bajpai J, Chandrasekharan A, Talreja V, Simha V, Chandrakanth MV, Rekhi B, Khurana S, Khan A, Vora T, Ghosh J, Banavali SD, Gupta S. Bajpai J, et al. Among authors: talreja v. Eur J Cancer. 2017 Nov;85:49-58. doi: 10.1016/j.ejca.2017.08.013. Epub 2017 Sep 8. Eur J Cancer. 2017. PMID: 28888849
Long term toxicity and tolerance of concurrent docetaxel with radiotherapy in cisplatin-ineligible head and neck cancer patients.
Patil VM, Kolkur M, Kumar Chinthala S, Waratkar G, Menon N, Noronha V, Ghosh Laskar S, Simha V, Talreja V, Dhumal S, Chandrasekharan A, Prabhash K. Patil VM, et al. Among authors: talreja v. Oral Oncol. 2022 Jul;130:105908. doi: 10.1016/j.oraloncology.2022.105908. Epub 2022 May 27. Oral Oncol. 2022. PMID: 35636079 No abstract available.
Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer.
Patil VM, Noronha V, Joshi A, Dhumal S, Mahimkar M, Bhattacharjee A, Gota V, Pandey M, Menon N, Mahajan A, Sable N, Kumar S, Nawale K, Mukadam S, Solanki B, Das S, Simha V, Abraham G, Chandrasekharan A, Talreja V, DSouza H, Srinivas S, Kashyap L, Banavali S, Prabhash K. Patil VM, et al. Among authors: talreja v. J Clin Oncol. 2019 Nov 10;37(32):3032-3041. doi: 10.1200/JCO.19.01076. Epub 2019 Sep 20. J Clin Oncol. 2019. PMID: 31539316 Clinical Trial.
Palliative chemotherapy in carcinoma nasopharynx.
Patil VM, Joshi A, Noronha V, Talreja V, Simha V, Dhumal S, Bandekar B, Chandrasekharan A, Prabhash K. Patil VM, et al. Among authors: talreja v. South Asian J Cancer. 2019 Jul-Sep;8(3):173-177. doi: 10.4103/sajc.sajc_230_18. South Asian J Cancer. 2019. PMID: 31489292 Free PMC article.
Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?
Joshi A, Noronha V, Patil VM, Chougule A, Bhattacharjee A, Kumar R, Goud S, More S, Ramaswamy A, Karpe A, Pande N, Chandrasekharan A, Goel A, Talreja V, Mahajan A, Janu A, Purandare N, Prabhash K. Joshi A, et al. Among authors: talreja v. Chemother Res Pract. 2017;2017:8196434. doi: 10.1155/2017/8196434. Epub 2017 Oct 23. Chemother Res Pract. 2017. PMID: 29201462 Free PMC article.
37 results